Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05727800 · ClinicalTrials.gov registry record · Phase 1
A Phase 1, First-in-human Study of VX-668
A Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 114
- Enrollment target
- 5
- Study locations
NCT05727800: Completed Phase 1 study of Alpha-1 Antitrypsin Deficiency, sponsored by Vertex Pharmaceuticals Incorporated.
NCT05727800 is a Phase 1 study of Alpha-1 Antitrypsin Deficiency that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 114 participants, below the 2,337-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (95% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05727800, a Phase 1 study of Alpha-1 Antitrypsin Deficiency, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 114 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-668
Study Locations (5)
Florida
- University of Florida - Gainesville
- Central Florida Pulmonary Group, P.A. - Orlando
Arizona
- Celerion - Tempe - Tempe
Kansas
- ICON Lenexa - Lenexa
Utah
- ICON Salt Lake City - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2023-02-08 |
| Est. Completion | 2024-02-13 |
| Phase | Phase 1 |
What the finished NCT05727800 record still lists
NCT05727800 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 2,337-participant average among 24 other Alpha-1 Antitrypsin Deficiency trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Alpha-1 Antitrypsin Deficiency appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05727800 lists 5 locations in 4 states (Florida, Arizona, Kansas).
Frequently Asked Questions
What is clinical trial NCT05727800 about?
NCT05727800 is a clinical study titled "A Phase 1, First-in-human Study of VX-668". The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-668 at various doses.
What is the current status of trial NCT05727800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 114 participants. The study started on 2023-02-08. Estimated completion is 2024-02-13.
What conditions does trial NCT05727800 study?
This clinical trial studies the following conditions: Alpha-1 Antitrypsin Deficiency.
What interventions are being tested in trial NCT05727800?
The interventions under investigation include: Placebo (DRUG), VX-668 (DRUG).
Who is sponsoring clinical trial NCT05727800?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05727800 being conducted?
This trial has 5 study locations across Arizona, Florida, Kansas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alpha-1 Antitrypsin Deficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05727800's enrollment target sits among peer trials
114 10th of 24 higher than 15 of 24 other Alpha-1 Antitrypsin Deficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alpha-1 Antitrypsin Deficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Gene Therapy for Alpha 1- Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study of KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of BEAM-302 in Adult Patients With Alpha-1 Antitrypsin Deficiency (AATD)
RECRUITING · Phase 1
-
Study of BMN 349 Single Dose in PiZZ and PiMZ/MASH Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Two Different Doses of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% in Participants With Alpha1-Antitrypsin Deficiency
COMPLETED · Phase 1
-
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI